These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28337954)

  • 1. Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Chen G; Guo Z; Liu M; Yao G; Dong J; Guo J; Ye C
    Oncol Res; 2017 Nov; 25(9):1567-1578. PubMed ID: 28337954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
    Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
    PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
    van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
    Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
    Alsaloumi L; Shawagfeh S; Abdi A; Basgut B
    Oncol Res Treat; 2020; 43(12):694-702. PubMed ID: 32950984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
    Natori A; Ethier JL; Amir E; Cescon DW
    Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
    Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
    Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
    BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
    Zhang ZC; Xu QN; Lin SL; Li XY
    PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant capecitabine for HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2017 Jul; 18(7):e375. PubMed ID: 28602775
    [No Abstract]   [Full Text] [Related]  

  • 12. Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials.
    Zhou W; Cao Y; Gou P; Zeng X; Hu X; Lin Z; Ye C; Chen L; Yao G
    Future Oncol; 2021 Dec; 17(35):4993-5002. PubMed ID: 34689590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
    Lemos Duarte I; da Silveira Nogueira Lima JP; Passos Lima CS; Deeke Sasse A
    Breast; 2012 Jun; 21(3):343-9. PubMed ID: 22425607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
    Jacquin JP; Jones S; Magné N; Chapelle C; Ellis P; Janni W; Mavroudis D; Martín M; Laporte S
    Breast Cancer Res Treat; 2012 Aug; 134(3):903-13. PubMed ID: 22270929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
    Muss HB; Polley MC; Berry DA; Liu H; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Kartcheske PA; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Sutton LM; Magrinat G; Parker BA; Hart RD; Grenier D; Hurria A; Jatoi A; Norton L; Hudis CA; Winer EP; Carey L
    J Clin Oncol; 2019 Sep; 37(26):2338-2348. PubMed ID: 31339827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer.
    Alagizy HA; Shehata MA; Hashem TA; Abdelaziz KK; Swiha MM
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):22-7. PubMed ID: 25528114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Untch M; Pérol D; Mayer EL; Cortes J; Nusch A; Cameron D; Barrios C; Delea T; Danyliv A; Mishra N; Gupta R; Pathak P; Fasching PA
    Eur J Cancer; 2024 May; 202():113977. PubMed ID: 38460476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials.
    Yin W; Pei G; Liu G; Huang L; Gao S; Feng X
    Oncotarget; 2015 Nov; 6(36):39365-72. PubMed ID: 26420815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis.
    Bai J; Yao X; Pu Y; Wang X; Luo X
    Front Oncol; 2023; 13():1245650. PubMed ID: 37954087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
    Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
    Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.